First Ascent Biomedical, a personalized oncology drug prediction platform, raised $6 million to accelerate lab openings, CEO Jim Foote, tells Axios exclusively.
Why it matters: The biotech startup offers patients new ways to seek treatment for their specific cancer profile.
